

患者まで届いている

再生医療 脂肪組織由来幹細胞を用いた 乳房再建術

*The Clinical Trial of breast reconstruction using adipose
derived stem cells after partial mastectomy*

陶山 淑子¹⁾ 森川 久未²⁾ 山本 康孝³⁾ 八木 俊路朗¹⁾ 中山 敏¹⁾
久留 一郎³⁾

Suyama, Yoshiko¹⁾/ Morikawa, Kumi²⁾/ Yamamoto, Yasutaka³⁾/ Yagi, Shunjiro¹⁾/ Nakayama, Bin¹⁾/
Hisatome, Ichiro³⁾

1) 鳥取大学医学部附属病院形成外科

2) 鳥取大学医学部附属病院次世代高度医療推進センター

3) 鳥取大学大学院医学系研究科機能再生医科学専攻再生医療学部門

1) Department of Plastic and Reconstructive Surgery, Tottori University Faculty of Medicine

2) Center for Promoting Next-Generation Highly advanced Medicine, Tottori University Hospital

3) Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics,
Tottori University Graduate School of Medical Science

E-mail : jippla@med.tottori-u.ac.jp

Key words

脂肪組織由来幹細胞 / 乳房再建術 / ADSCs / 乳房温存術

Summary

The patients of breast cancer are increasing, and often are diagnosed in the early stage. So the cases treated by partial mastectomy increase. Partial mastectomy sometimes lefts defects that is difficult to reconstruct using usual procedures such as flaps or implants.

We underwent the clinical trial for the procedure to reconstruct the defects using autologous adipose derived stem cells (ADSCs)-enriched fat graft based on preclinical data. Five patients without recurrences and metastasis after the partial mastectomy were selected to undergo the procedure.

The result was that no infection and no recurrence occurred through 12 months, and the thickness and volume of treated area were kept. Patients were satisfied with the results. This trial demonstrates the safety and efficacy of this procedure.

The goal of this trial is to progress this procedure to the health insurance treatment. We have to advance the next step to establish the safety and efficiency of this procedure.

はじめに

女性の悪性腫瘍による死因の中で乳がんは近年増加

の一途を辿っている。我が国における乳がんの発生率は欧米諸国に比べると2分の1～3分の1程度と低い
が、近年の統計では、日本人女性のがんの中では最